IP Library Granted Patent US 7,244,760
Granted Patent B2
US 7,244,760 · App. 10/152,152 · Granted Jul 17, 2007

Methods for preparation and use of psorospermin analogs

Assignees: Board of Regents, The University of Texas System; Cylene Pharmaceuticals, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,244,760
App. No.
10/152,152
Granted
Jul 17, 2007
Kind
B2
Abstract

Psorospermin is a cytotoxic dihydroflranoxanthone that has found to exhibit significant activity against various tumor cell lines. Unfortunately, psorospermin is no longer readily available from its natural plant source. The present invention is directed to a method for preparing psorospermin and psorospermin analogs. Methods are also disclosed for utilizing psorospermin analogs to inhibit cellular proliferation.

Claims (10)

1. A method of inhibiting cell proliferation, the method comprising contacting a cancer cell with an effective amount of a compound having the formula:

wherein each R 1 -R 4 and R 6 is independently H, OH, O-alkyl, halogen, or alkyl;

R 5 is H, O-alkyl, or alkyl; and

R 8 is alkyl.

2. A method to inhibit proliferation of a cancer cell, wherein the cancer cell is a pancreatic cancer cell, prostate cancer cell, myeloma cell, ovarian cancer cell, or breast cancer cell, which comprises contacting said cell with an effective amount of a compound of the formula:

wherein R 1 -R 4 , R 6 and R 8 are as defined in claim 1 and R 5 is H, OH, O-alkyl or alkyl.

3. The method of claim 2 , wherein the cancer cell is a multi-drug resistant (MDR) cancer cell.

4. The method of claim 3 , wherein the MDR cancer cell is resistant to a topoisomerase II inhibitor.

5. The method of claim 3 , wherein MDR is mediated by MRP-1 or glycoprotein.

6. The method of claim 2 , wherein the cell is in a mammal.

Assignments (7)
CONFIRMATORY LICENSE Recorded Mar 15, 2017
From: UNIVERSITY OF TEXAS, AUSTIN
To: NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR
Reel/Frame 042017/0207 →
CONFIRMATORY LICENSE Recorded Mar 8, 2017
From: UNIVERSITY OF TEXAS, AUSTIN
To: NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR
Reel/Frame 041912/0801 →
CONFIRMATORY LICENSE Recorded Jul 1, 2015
From: UNIVERSITY OF TEXAS, AUSTIN
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 036053/0863 →
EXECUTIVE ORDER 9424, CONFIRMATORY LICENSE Recorded May 21, 2008
From: UNIVERSITY OF TEXAS AUSTIN
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 020975/0759 →
CHANGE OF NAME Recorded Feb 17, 2004
From: CYTERNEX, INC.
To: CYLENE PHARMACEUTICALS, INC.
Reel/Frame 015016/0960 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 23, 2002
From: HURLEY, LAURENCE; FELLOWS, INGRID
To: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
Reel/Frame 013312/0174 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 17, 2002
From: SCHWAEBE, MICHAEL KENRIC; WHITTEN, JEFFREY PAUL
To: CYTERNEX, INC.
Reel/Frame 013294/0545 →
Continuity (2)
Provisional Application 6029218900 · May 18, 2001
Related Publication 20030120093A1 · Jun 26, 2003